New therapeutic approach with ozoile® to the EAC eczema, a chronic and annoying pathology

The Eczema of the external auditory canal (EAC) is a challenge for the otolaryngologist and it’s a pathology that can annoy the patients and, in the most extreme cases, compromise their quality of life. Hence patients with eczema of EAC are exposed to a greater number of bacterial (acute bacterial otitis externa) or fungal (otomycosis) infections. The therapies proposed as of now for chronic eczematous external otitis (more than 3 months) are empirical. The most widely used drugs in this condition are topical corticosteroids which unfortunately can lead to dehydration of the skin, hypotropism with a reduction in their effectiveness over time Ozoile® (Stable Ozonides with Vitamin E acetate) acts as a biological inducer, regulates the main metabolic pathways, stimulates the endogenous defense system and through the regulation of gene transcription promotes tissue regeneration and damage-injury repair. This biological inducer has anti-inflammatory, anti-itching and anti-microbial action. Based on these results, the author used Ozoile® for the treatment of chronic eczematous external otitis (symptoms lasting more than three months). Sixty patients suffering from chronic eczematous otitis externa (CEOE) were recruited and given 1 month of treatment with 5 drops per ear in the morning and in the evening. Through a visual analogue scale (minimum score 0 and maximum 10 depending on the severity of the symptoms) the parameters itching, secretions, flaking and complications were evaluated at the beginning of the treatment (time 0) and at one month (time 1). After the treatment the results were as follow: 62.5% itching reduction, desquamation reduction by 72%, reduction of secretions by 80%. Total absence of side effects. We can conclude that Ozoile® (Stable Ozonides with Vitamin E acetate) has an excellent "outcome" in EAC eczema even for prolonged periods and is a manageable and complication-free biological inducer.

Broad-Spectrum Acquired Resistance in Barley Induced by the Pseudomonas Pathosystem Shares Transcriptional Components with Arabidopsis Systemic Acquired Resistance

Inducible resistance responses play a central role in the defense of plants against pathogen attack. Acquired resistance (AR) is induced alongside defense toward primary attack, providing broad-spectrum protection against subsequent pathogen challenge. The localization and molecular basis of AR in cereals is poorly understood, in contrast with the well-characterized systemic acquired resistance (SAR) response in Arabidopsis. Here, we use Pseudomonas syringae as a biological inducer of AR in barley, providing a clear frame of reference to the Arabidopsis–P. syringae pathosystem. Inoculation of barley leaf tissue with the nonadapted P. syringae pv. tomato avrRpm1 (PstavrRpm1) induced an active local defense response. Furthermore, inoculation of barley with PstavrRpm1 resulted in the induction of broad-spectrum AR at a distance from the local lesion, “adjacent” AR, effective against compatible isolates of P. syringae and Magnaporthe oryzae. Global transcriptional profiling of this adjacent AR revealed similarities with the transcriptional profile of SAR in Arabidopsis, as well as transcripts previously associated with chemically induced AR in cereals, suggesting that AR in barley and SAR in Arabidopsis may be mediated by analogous pathways.